Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #52 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Bliss GVS Pharma Limited (this stock) | 7,051 | 61.4 | 10.9% | 332.8% | 0.23% | 66 | 33 | 52 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 286 | 75 | 51 | ₹ |
| March 31, 2026 | 257 | 45 | 37 | ₹ |
| Dec. 31, 2025 | 218 | 41 | 25 | ₹ |
| Sept. 30, 2025 | 244 | 41 | 29 | ₹ |
| June 30, 2025 | 207 | 63 | 44 | ₹ |
| March 31, 2025 | 198 | 23 | 17 | ₹ |
| Dec. 31, 2024 | 210 | 36 | 26 | ₹ |
| Sept. 30, 2024 | 218 | 36 | 26 | ₹ |
| June 30, 2024 | 184 | 30 | 22 | ₹ |
| March 31, 2024 | 198 | -4 | -5 | ₹ |
| Dec. 31, 2023 | 201 | 40 | 29 | ₹ |
| Sept. 30, 2023 | 212 | 59 | 43 | ₹ |
| June 30, 2023 | 160 | 22 | 14 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 927 | 190 | 135 |
| March 31, 2025 | 810 | 126 | 90 |
| March 31, 2024 | 770 | 117 | 82 |
| March 31, 2023 | 752 | 106 | 77 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 139 | -38 | -89 | 57 | 82 |
| March 31, 2025 | 106 | -75 | -30 | 76 | 30 |
| March 31, 2024 | 152 | -133 | -21 | 28 | 124 |
| March 31, 2023 | 34 | -8 | -25 | 94 | -59 |
| March 31, 2022 | 135 | -93 | -24 | 0 | 135 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 1,492 | 1,232 | 1,182 | 3 | 0 | 946 | 236 | 35 | 451 | 151 |
| March 31, 2025 | 1,301 | 1,092 | 1,040 | 51 | 20 | 819 | 172 | 24 | 397 | 126 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
